The purpose of this study is find targeted treatment for patients with advanced cancer that has a actionable genomic variant revealed by genomic testing. Tissue from your cancer must be sent for genomic screening. You must have an advanced solid tumor, mulitple myeloma or B cell non-Hodgkin lymphona for which standard treatment options are no longer available.
Contact phone
Carolyn Krahulik | 517.364.2811
Contact email
Principal investigator
Gordon Srkalovic, MD, PhD
Trial Category
Trial SubCategory
All tumor types